NanoediT: Nanoneedle-mediated Genomic Editing for Hypoimmunogenic Regulatory T Cell Manufacturing

Regulatory T cells (Tregs) are immune cells that prevent harmful inflammation. Modified Tregs, equipped with a synthetic receptor called a CAR, are an emerging therapy for autoimmune diseases and transplant rejection. However, current treatments must be made individually for each patient, making them complex, slow, and extremely expensive to produce.

A more practical solution is to create universal “off-the-shelf” Treg therapies from healthy donors. For these donor cells to be used safely, they must be altered so the patient’s immune system does not reject them. This requires precise genome editing, but existing methods are either inefficient or damage Tregs, preventing progress.
NanoediT aims to overcome this barrier using a new nanoneedle-based technique to deliver gene editors gently and effectively into Tregs. This approach could enable large-scale production of immune-evasive CAR-Tregs, greatly reducing costs and improving access to advanced therapies for autoimmune conditions, transplants, and other inflammatory diseases